Influence
February 28, 2025

Predicting Alzheimer’s disease subtypes and understanding their molecular characteristics in living patients with transcriptomic trajectory profiling

Kun Huang, PhD

Published in the Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association. Here is a link to the article.

Regenstrief Institute authors: Kun Huang, PhD

This study addresses the challenge of identifying molecular mechanisms in living Alzheimer’s disease (AD) patients to support prognosis and precision medicine. Researchers applied an optimal transport-based method to transfer AD subtype labels from ROSMAP monocyte samples to peripheral blood mononuclear cell samples in the ADNI and ANMerge cohorts. Using graph-based transcriptomic mapping, differential expression, pathway analysis, diffusion pseudotime analysis, and survival analysis with real follow-up data, the study examined disease progression and potential prognostic biomarkers. The results confirmed accurate subtype label transfer and revealed that genes and pathways related to neutrophil degranulation, acute immune response, and IL-6 signaling are significantly associated with AD progression. The findings contribute to understanding AD heterogeneity and support the development of personalized treatment strategies.

Authors:
Xiaoqing Huang 1, Asha Jacob Jannu 2, Ziyan Song 1, Nur Jury-Garfe 3, Cristian A Lasagna-Reeves 3; Alzheimer’s Disease Neuroimaging Initiative; Travis S Johnson 1, Kun Huang 1, Jie Zhang 4
Affiliations

Affiliations

1Department of Biostatistics & Health Data Science, Indiana University School of Medicine, Indianapolis, Indiana, USA.

2Department of Biohealth Informatics, Indiana University School of Medicine, Indianapolis, Indiana, USA.

3Department of Anatomy, Cell Biology & Physiology, Indiana University School of Medicine, Indianapolis, Indiana, USA.

4Department of Medical & Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana, USA.

Related News

image of a doctor consulting with a patient

Scalable approach could improve early detection of cognitive impairment in primary care

Regenstrief-led study evaluates how existing health data and patient-reported information could help clinicians identify individuals who need further assessmentEarly

Christopher Callahan, MD

Regenstrief Institute scientist named next president and CEO of Regenstrief Foundation 

Longtime Regenstrief investigator and former IU Center for Aging Research director will assume Foundation leadership in summer 2027.  Christopher

Rachel Patzer, PhD, MPH

Building trust in healthcare AI through data and evidence

As artificial intelligence rapidly transforms healthcare, innovation alone is not enough. Health systems need evidence that AI tools are

doctor using electronic health record

Data expertise helps researchers understand how clinical tools are used in real-world care

Regenstrief Data Services (RDS) provided critical health data and specialized expertise to support research examining clinical decision-support use across